Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2104981 | 0.91 | EPHX2 (0.40) | EPHX2CHRM4 | |
| SCHEMBL2102934 | 0.91 | EPHX2 (0.43) | EPHX2CHRM4 | |
| SCHEMBL2103195 | 0.89 | EPHX2 (0.46) | EPHX2CHRM4 | |
| SCHEMBL18914047 | 0.76 | EPHX2 (0.46) | EPHX2CHRM4 | |
| SCHEMBL4355006 | 0.76 | CA1 (0.46) | EPHX2CHRM4 | |
| SCHEMBL4439325 | 0.74 | CA1 (0.50) | EPHX2CHRM4 | |
| SCHEMBL3503020 | 0.74 | CA1 (0.50) | EPHX2CHRM4 | |
| SCHEMBL666285 | 0.70 | CA1 (0.52) | — | |
| SCHEMBL1380380 | 0.70 | EPHX2 (0.38) | EPHX2CHRM4ABL1BCR | |
| SCHEMBL68732 | 0.70 | EPHX2 (0.42) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | claimed |
| US-8653081-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-02-18 | — | — | US | claimed |
| US-20130296335-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2013-11-07 | — | — | US | claimed |
| US-8410108-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2013-04-02 | — | — | US | claimed |
| US-8129358-B2 | Substituted pyrazole and triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | claimed |
| EP-1912972-B1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2011-09-28 | — | — | EP | claimed |
| US-7902240-B2 | Kinesin spindle protein (KSP); anticancer agents; antiproliferative agents; e.g. N-((S)-3-amino-4-fluorobutyl)-N ((R)-1-(1-benzyl-3-(2,5-difluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)nicotinamide | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | claimed |
| US-20100210634-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | claimed |
| US-7718657-B2 | Certain indanyl urea modulators of the cardiac sarcomere | CYTOKINETICS, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-20100034813-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | claimed |
| US-7626040-B2 | Substituted imidazole compounds as KSP inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | claimed |
| EP-2091926-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | Novartis AG (CH) | 2009-08-26 | — | — | EP | claimed |
| EP-1959962-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG | 2008-08-21 | — | — | US | claimed |
| WO-2008063912-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | claimed |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007078815-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-12 | — | — | WO | claimed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | claimed |
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| WO-2006060810-A1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210634-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, MYLK2 | EPHX2 3695/4885CHRM4 308/4885ABL1 2656/4885 |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | KIF5B, KIF2C, KIF18B | EPHX2 4759/4885CHRM4 4692/4885ABL1 2771/4885 |
| US-20130296335-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TNNI3, MYLK2, TNNT2 | EPHX2 3572/4885CHRM4 392/4885ABL1 2030/4885 |
| US-20100034813-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP3A43, ABCG2, CYP3A7 | EPHX2 3943/4885CHRM4 4602/4885ABL1 3009/4885 |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP3A43, ABCG2, CYP3A7 | EPHX2 3943/4885CHRM4 4602/4885ABL1 3009/4885 |
| US-20070197507-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | EPHX2 3695/4885CHRM4 308/4885ABL1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.